Claire Charra-Brunaud

Claire Charra-Brunaud

Auto-generated profile, based on publicly available information

Claire Charra-Brunaud

Institut de Cancérologie de Lorraine, Department of Radiation Oncology, Vandœuvre-lès-Nancy, France

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
XSXavier Sastre-Garau
Xavier Sastre-Garau
MDMamadou Diop
Mamadou Diop
FMFernando Martin
Fernando Martin
GDGilles Dolivet
Gilles Dolivet
FMFrédéric Marchal
Frédéric Marchal
AHAlexandre Harlé
Alexandre Harlé
Purpose: Use of circulating tumor DNA (ctDNA) for diagnosis is limited regarding the low number of target molecules in early-stage tumors. Human papillomavirus (HPV)–associated carcinomas represent a privileged model using circulating viral DNA (ctHPV DNA) as a tumor marker. However, the plurality of HPV genotypes represents a challenge. The next-generation sequencing (NGS)-based CaptHPV approach is able to characterize any HPV DNA sequence. To assess the ability of this method to establish the diagnosis of HPV-associated cancer via a blood sample, we analyzed ctHPV DNA in HPV-positive or HPV-negative carcinomas. Experimental Design: Patients (135) from France and Senegal with carcinoma developed in the uterine cervix (74), oropharynx (25), oral cavity (19), anus (12), and vulva (5) were prospectively registered. Matched tumor tissue and blood samples (10 mL) were taken before treatment and independently analyzed using the CaptHPV method. Results: HPV prevalence in tumors was 60.0% (81/135; 15 different genotypes). Viral analysis of plasmas compared with tumors was available for 134 patients. In the group of 80 patients with HPV-positive tumors, 77 were also positive in plasma (sensitivity 95.0%); in the group of 54 patients with HPV-negative tumors, one was positive in plasma (specificity 98.1%). In most cases, the complete HPV pattern observed in tumors could be established from the analysis of ctHPV DNA. Conclusions: In patients with carcinoma associated with any HPV genotype, a complete viral genome characterization can be obtained via the analysis of a standard blood sample. This should favor the development of noninvasive diagnostic tests providing the identification of personalized tumor markers. See related commentary by Rostami et al., p. 5158

24 November 2025 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
MBMarie Bruand
Marie Bruand
DKDorra Kanoun
Dorra Kanoun
FTFlorence Le Tinier
Florence Le Tinier
CRChristine Rousset-Jablonski
Christine Rousset-Jablonski
SNSarah Nadjafizadeh
Sarah Nadjafizadeh
JFJean-Christophe Faivre
Jean-Christophe Faivre

28 August 2025 in Brachytherapy
Verified
Journal Article
Open access
LLLydie Lemoine
Lydie Lemoine
VAVirginie Adam
Virginie Adam
JSJulia Salleron
Julia Salleron
CCChristelle Cuisinier
Christelle Cuisinier
JPJuly Perrin
July Perrin
SRSophie Renard
Sophie Renard
Removal of brachytherapy applicator is routinely performed under premedication including Kalinox® gas inhalation without general anesthesia. The applicator removal is nevertheless associated with discomfort, anxiety or pain. We assessed the adjunction of formal hypnosis during this procedure. This prospective, randomized, single-center study focused on adult patients undergoing pelvic brachytherapy applicator removal. Patients were randomly assigned to (1:1): standard management including Kalinox® (control group) vs. standard management including Kalinox® accompanied by formal hypnosis (hypnosis group). The primary endpoint was anxiety using the State-Trait Anxiety Inventory (STAI) Y-A form (state anxiety). A secondary endpoint was pain after applicator removal (numerical scale). A total of 68 patients (mean age, 51.9 years) were included (cervical cancer, 86.6%). Before applicator removal, mean (SD) STAI Y-A anxiety score was 45.9 (5.6) in the control group vs. 47.5 (5.9) in the hypnosis group. After applicator removal, the scores were 48.1 (4.3) versus 47.7 (4.2), respectively (p = 0.76). Pain score was not significantly different after applicator removal (p = 0.055) in the hypnosis group compared to the control group: 1.29 (1.72) versus 0.71 (1.51), respectively. There were no significant differences between the 2 groups concerning caregiver satisfaction with patient management (p = 0.27), ease of realization (p = 0.17) and caregiver comfort (p = 0.42). This study failed to demonstrate a substantial benefit of formal hypnosis on anxiety in patients undergoing pelvic brachytherapy applicator removal. But this study suggests that the use of hypnotic communication techniques enables a positive attitude to patient care, thus reinforcing the patient-caregiver relationship.

29 October 2024
Verified
Other
Open access
XSXavier Sastre-Garau
Xavier Sastre-Garau
MDMamadou Diop
Mamadou Diop
FMFernando Martin
Fernando Martin
GDGilles Dolivet
Gilles Dolivet
FMFrédéric Marchal
Frédéric Marchal
AHAlexandre Harlé
Alexandre Harlé
SNPs and indels for each cases

29 October 2024
Verified
Other
Open access
XSXavier Sastre-Garau
Xavier Sastre-Garau
MDMamadou Diop
Mamadou Diop
FMFernando Martin
Fernando Martin
GDGilles Dolivet
Gilles Dolivet
FMFrédéric Marchal
Frédéric Marchal
AHAlexandre Harlé
Alexandre Harlé

29 October 2024
Verified
Other
Open access
XSXavier Sastre-Garau
Xavier Sastre-Garau
MDMamadou Diop
Mamadou Diop
FMFernando Martin
Fernando Martin
GDGilles Dolivet
Gilles Dolivet
FMFrédéric Marchal
Frédéric Marchal
AHAlexandre Harlé
Alexandre Harlé
Supplementary Figure 1: Insertion patterns for all cases harboring HPV DNA integration. Two junctions co-linear (2J-CL) (a), two junctions non-linear (2J-NL) (b), multiple-junctions clustered (MJ-CL) (c) and multiple-junctions scattered (MJ-SC) (d). Insertions are presented with a black line when present in tissue only, a red line when present in plasma only and a dashed black and red line when present in both tissue and plasma. All genomics coordinates use Hg38 reference. Double-dash is used when the insertion is outside an intronic or exonic region of a gene and the closest gene is reported.